广告
加载中

AI原料公司天鹜科技融资2亿元 化妆品原料研发仅需半年?

亿邦动力 2026-03-18 15:39
亿邦动力 2026/03/18 15:39

邦小白快读

EN
全文速览

AI原料公司天鹜科技通过技术创新大幅提升研发效率,值得关注的实操干货包括融资进展和技术突破。

1. 公司完成超2亿元的A+轮融资,成立仅三年融资历程丰富,包括2022年种子轮和2024年Pre-A轮及A轮融资,显示市场认可度高。

2. AI大模型AccelProtein™自动设计蛋白质序列,预测功能并优化性质如耐热、耐碱和活性更强,显著缩短研发周期。

3. 优化时长从2至5年减少到2至6个月,实验数量从成千上万降至约100个,降低研发成本。

4. 应用案例包括化妆品原料研发周期缩短至6个月,以及与金赛药业合作提升蛋白质耐碱性4倍,成功用于5000升规模生产。

天鹜科技的AI技术在原料研发中创新应用,为品牌提供产品开发和消费趋势洞察的干货。

1. 品牌营销启示:技术服务覆盖化妆品领域,将原料研发周期大幅缩短,加速新品上市,迎合高效创新趋势。

2. 产品研发突破:AI优化蛋白质性质(如活性更强、耐碱性提升),提升产品质量,可应用于化妆品原料,满足消费者对高效、安全产品的需求。

3. 消费趋势观察:AI驱动研发成为行业新动向,合作案例(如金赛药业)显示向数字化和个性化延伸,反映用户行为追求科技赋能产品。

4. 实际应用:2024年扩展至化妆品领域,研发周期减至半年,提供快速响应市场变化的实操案例。

天鹜科技的融资和技术突破揭示增长市场与商业机会,卖家需关注政策风险低、合作模式灵活的干货。

1. 增长市场机会:公司快速融资(A+轮超2亿元),显示AI研发领域潜力大,可拓展至制药和化妆品等高需求领域。

2. 消费需求变化:AI缩短研发周期至2-6个月,减少实验需求,应对市场对快速创新产品的高需求变化。

3. 合作方式与机会:技术服务模式(如与金赛药业合作提升耐碱性),提供定制化方案;子公司飞因科设计双靶点药物分子,开启新合作机会。

4. 风险提示与学习点:技术减少实验数量和周期,降低研发失败风险;机会在于学习AI优化生产,实现商业模式创新。

天鹜科技的AI技术优化生产需求,为工厂提供数字化启示和商业机会的干货。

1. 产品生产需求:AI大模型优化蛋白质性质(如耐热、耐碱),使其更适应工业化环境,提升生产效率和产品稳定性。

2. 商业机会:应用案例包括5000升规模生产中耐碱性提升4倍,显示AI可助力规模化生产,减少资源浪费。

3. 推进数字化启示:研发周期缩短至2-6个月,实验减至100个,启示工厂通过AI加速流程,降低试错成本。

4. 电商启示:技术服务模式可整合到供应链,如化妆品原料快速开发,支持电商需求响应。

天鹜科技的AI大模型解决行业痛点,服务商可关注新技术趋势和解决方案的干货。

1. 行业发展趋势:AI驱动蛋白质设计成为新动向,跨领域应用(从制药到化妆品),显示技术融合趋势。

2. 新技术:自主研发的AccelProtein™模型自动设计序列、预测功能,优化性质如活性更强,提供高效工具。

3. 客户痛点解决方案:针对研发周期长、实验多痛点,AI缩短优化至2-6个月,实验减至100个,降低客户成本。

4. 实际应用:案例包括化妆品原料周期缩短和子公司设计药物分子,提供可复制的解决方案。

天鹜科技的技术服务模式满足平台需求,平台商需关注合作机会和运营管理的干货。

1. 商业需求与问题:企业寻求高效研发(如周期缩短),平台可通过整合AI服务解决需求,如合作对象从药企扩展到化妆品公司。

2. 平台做法:技术服务模式(融资支持商业落地),提供定制化设计,案例包括与金赛药业合作优化生产。

3. 招商机会:快速融资历程显示行业吸引力,平台可招商类似技术企业,拓展生态。

4. 风险规避:AI减少实验数量和周期,降低运营风险;启示平台管理需注重技术整合以规避低效。

天鹜科技的创新应用推动产业新动向,研究者可关注技术突破和商业模式的干货。

1. 产业新动向:AI在蛋白质设计中加速研发,跨领域扩展(从创新药到化妆品),显示产业融合趋势。

2. 新问题:如何优化模型适应不同生产环境(如耐碱性提升),启示研究需解决规模化应用挑战。

3. 商业模式:技术服务模式融资支持发展,案例包括子公司设计双靶点药物分子,提供研究样本。

4. 政策启示:技术减少实验需求,可能影响法规框架,建议研究如何平衡创新与安全。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

AI ingredient company Tianwu Technology has significantly boosted R&D efficiency through technological innovation, with noteworthy highlights including funding progress and technical breakthroughs.

1. The company completed a Series A+ funding round exceeding 200 million yuan, with a rich funding history since its establishment just three years ago—including a 2022 seed round and 2024 Pre-A and Series A rounds—demonstrating strong market recognition.

2. Its AI model, AccelProtein™, automatically designs protein sequences, predicts functionality, and optimizes properties such as heat resistance, alkali tolerance, and enhanced activity, significantly shortening R&D cycles.

3. Optimization time has been reduced from 2–5 years to 2–6 months, while the number of required experiments dropped from thousands to around 100, lowering R&D costs.

4. Application cases include cutting cosmetic ingredient development time to 6 months and a collaboration with Jinsai Pharmaceutical that improved protein alkali resistance by fourfold, successfully scaling to 5,000-liter production.

Tianwu Technology’s AI innovations in ingredient R&D offer brands actionable insights for product development and consumer trend analysis.

1. Marketing implications: The technology’s application in cosmetics drastically shortens ingredient development cycles, accelerating time-to-market and aligning with the trend toward efficient innovation.

2. Product R&D breakthroughs: AI-optimized protein properties—such as heightened activity and improved alkali resistance—enhance product quality for cosmetics, meeting consumer demand for high-efficacy, safe products.

3. Consumer trend observation: AI-driven R&D is emerging as an industry trend, with collaborations like Jinsai Pharmaceutical reflecting a shift toward digital and personalized solutions driven by tech-savvy consumer behavior.

4. Practical application: Expansion into cosmetics in 2024 reduced development cycles to six months, offering a case study in rapid market responsiveness.

Tianwu Technology’s funding and technical advances reveal growth opportunities in a low-regulatory-risk sector with flexible partnership models.

1. Growth market potential: Rapid fundraising (over 200 million yuan in Series A+) signals strong prospects in AI-driven R&D, extendable to high-demand sectors like pharmaceuticals and cosmetics.

2. Evolving consumer demand: AI slashes R&D cycles to 2–6 months and reduces experimental needs, addressing market expectations for fast innovation.

3. Partnership opportunities: Service-based models, such as the Jinsai collaboration on alkali resistance, offer customized solutions; subsidiary Feiyinke’s dual-target drug molecule designs open additional avenues.

4. Risk mitigation and takeaways: Fewer experiments and shorter cycles lower R&D failure risks; sellers can learn from AI-optimized production to innovate business models.

Tianwu’s AI technology optimizes production needs, offering factories digitalization insights and commercial opportunities.

1. Production requirements: AI models enhance protein properties like heat/alkali tolerance, improving adaptability to industrial environments and boosting efficiency and stability.

2. Business opportunities: Case studies, including 4x alkali resistance in 5,000-liter production, demonstrate AI’s potential to scale manufacturing while reducing waste.

3. Digitalization insights: R&D cycles shortened to 2–6 months and experiments cut to ~100 suggest factories can use AI to accelerate processes and lower trial costs.

4. E-commerce relevance: Service models can integrate into supply chains—e.g., rapid cosmetic ingredient development—to support agile responses to e-commerce demand.

Tianwu’s AI model addresses industry pain points, highlighting new tech trends and scalable solutions for service providers.

1. Industry trends: AI-driven protein design is gaining traction across sectors (pharma to cosmetics), reflecting broader technology convergence.

2. Innovation focus: The proprietary AccelProtein™ model automates sequence design, function prediction, and property optimization (e.g., enhanced activity), offering an efficient toolset.

3. Pain point resolution: AI reduces optimization time to 2–6 months and experiments to ~100, addressing client challenges around lengthy R&D and high costs.

4. Practical applications: Cases like cosmetic ingredient acceleration and drug molecule design by subsidiaries provide replicable solution frameworks.

Tianwu’s service model meets platform needs, highlighting partnership opportunities and operational efficiencies for marketplace operators.

1. Business demands: Companies seek faster R&D (e.g., shorter cycles); platforms can integrate AI services to serve clients from pharma to cosmetics.

2. Platform strategy: Service-based models (supported by funding) enable customized designs, as seen in the Jinsai collaboration for production optimization.

3. Partnership potential: Rapid fundraising signals sector attractiveness; platforms can onboard similar tech firms to expand ecosystems.

4. Risk management: AI reduces experiment volume and cycle times, mitigating operational risks; platforms should prioritize tech integration to avoid inefficiencies.

Tianwu’s innovative applications highlight industry shifts, offering researchers insights into technical advances and business models.

1. Industry trends: AI accelerates protein design, with cross-sector expansion (e.g., novel drugs to cosmetics) indicating convergence.

2. Research challenges: Optimizing models for diverse production environments (e.g., alkali resistance) underscores the need to address scalability issues.

3. Business models: Service-oriented approaches, funded progressively, provide case studies like dual-target drug design for analysis.

4. Policy implications: Reduced experimental demands may impact regulatory frameworks; researchers should explore balancing innovation with safety standards.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】又一家AI原料研发公司,完成新一轮融资。

日前,天鹜科技完成超2亿元的A+轮融资。该公司成立于2021年,主打“AI蛋白质设计”。天鹜科技创始团队来自上海交通大学。

2022年3月,该公司成立不足半年时,便完成数千万元的种子轮融资,2024年又完成了Pre-A轮和A轮融资。同年,该公司技术服务覆盖至化妆品领域,可将化妆品原料的研发周期缩短至6个月。

据悉,该公司自主研发的AI大模型AccelProtein™,可自动设计蛋白质序列,自主预测蛋白质功能,并辅助优化蛋白质性质,使其更适应工业化生产环境,例如更耐热、耐碱、活性更强等。

值得注意的是,在AI大模型的辅助下,优化时长从2至5年缩短至2至6个月,且所需实验数量从成千上万个减少至约100个。

从天鹜科技官方微信公众号的信息来看,成立之初,公司的合作对象以药企为主,致力于创新药的研发,当时的目标是与优质药企合作。目前,公司专注于AI蛋白质设计服务,Pre-A轮融资便主要用于加速相关大模型的商业落地。

2024年6月,天鹜科技与金赛药业合作,通过AI大模型,将一种蛋白质的耐碱性提升了4倍,并成功应用于5000升规模的放大生产中。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0